Spot Trading’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$14.6M Buy
169,000
+18,200
+12% +$1.46M 0.25% 47
2017
Q2
$11.6M Buy
150,800
+90,800
+151% +$6.44M 0.23% 54
2017
Q1
$4.16M Sell
60,000
-93,500
-61% -$6.28M 0.14% 124
2016
Q4
$9.09M Buy
153,500
+26,600
+21% +$1.64M 0.21% 84
2016
Q3
$8.41M Buy
126,900
+62,200
+96% +$3.85M 0.17% 106
2016
Q2
$3.5M Sell
64,700
-11,900
-16% -$652K 0.06% 435
2016
Q1
$3.96M Buy
+76,600
New +$3.98M 0.07% 374
2015
Q4
Sell
-17,200
Closed -$1.07M 4135
2015
Q3
$1.07M Buy
17,200
+16,300
+1,811% +$1.28M 0.01% 1528
2015
Q2
$76K Buy
+900
New +$70K ﹤0.01% 3175

Other funds holding XBI

Spot Trading's XBI Position: Q3 2017 in Review

Spot Trading sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2017, closing a stake of 23,954 shares — an estimated $1.92M sold.

Spot Trading first reported a position in XBI in Q2 2016 and held it in 3 quarters. The position peaked at $7.51M in Q2 2016. 349 funds tracked by Wall St. Rank hold XBI as of Q3 2017.

  • Spot Trading reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2017 after selling out during the quarter.
  • Spot Trading sold 23,954 State Street SPDR S&P Biotech ETF shares in Q3 2017, an estimated $1.92M.
  • Spot Trading first reported a position in State Street SPDR S&P Biotech ETF in Q2 2016 and held it in 3 quarters.
  • Spot Trading's State Street SPDR S&P Biotech ETF position peaked at $7.51M in Q2 2016.
  • 349 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.